Jacobson Pharma's IFRS net income for fiscal 2022 was HK$187.705 million, up 0.7% from HK$186.308 million in the previous year. Revenue increased 10.3% to HK$1.595 billion versus HK$1.446 billion a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept